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G R A P H I C A L A B S T R A C T
A B S T R A C T
Surface plasmon resonance technique is particularly interesting in immunology because it has the potential to
visualize label-free antigen-antibody interactions in real-time, thus enabling antibody detection and monitoring.
Herein we release the guidelines for the correct use of a method to detect specific antibodies directly in Multiple
Sclerosis patients’ sera using a glucopeptide-based label-free biosensor. The protocol describes the strategy
employed for the immobilization of glucopeptide antigen onto a gold sensor chip and the evaluation of the
specific binding of serum antibodies to the immobilized antigen.
 Label-free method for the real time screening of disease-specific antibodies within a few minutes;
 The described protocol employs small quantities of glucopeptide antigen and blood serum samples saving
method-cost;
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1Stability of the immobilized glucopeptide antigen guarantees the regeneration of the surface allowing re-use
the immunosensor with high automated throughput.
he antibodies detected using the described methodology can be evaluated as biomarkers of Multiple Sclerosis.
he SPR detection system is able to characterize antibodies significantly different from those evaluated in the
lassical enzyme-linked immunosorbent assays (ELISA).
ã 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
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ethod details
One of the major challenges in Multiple Sclerosis diagnosis is the set-up of simple
mmunodiagnostic methods. In fact, the gold standard for the diagnosis and prognosis of the disease
s, up to now, the use of magnetic resonance imaging markers and cerebrospinal fluid analysis. Surface
lasmon resonance (SPR) technique has been successfully used to measure the binding of a large
umber of biomolecular interactions including those of antibodies with cognate antigens [1]. The
ethod for anti-glucopeptide antibody detection in Multiple Sclerosis described herein enables label-
ree specific antibody detection directly in patients’ sera, using a previously described glucopeptide
ntigen, termed CSF114(Glc) [2]. A direct comparison of antibody profiles in Multiple Sclerosis
atients’ sera by means of enzyme-linked immunosorbent assay (ELISA) and SPR-based biosensor
videnced that, from a diagnostic point of view, results should be independently evaluated [3].
lucopeptide antigen immobilization: selection of the immobilization buffer
The glucopeptide CSF114(Glc) was prepared by microwave-assisted solid phase peptide synthesis
nd further characterized by mass spectrometry and analytical HPLC as described elsewhere [4]. A
tock solution of CSF114(Glc) was prepared in pure water (1 mg/mL) and stored at +4 C. Immediately
rior to immobilization procedure, peptide stock solution was diluted in the immobilization buffer to
 final concentration of 10 mg/mL.
Sensor chip CM5 (GE Healthcare, Uppsala, Sweden) was inserted into the SPR detector (Biacore
100, GE Healthcare). The running buffer HBS-EP+ 10 (0.1 M HEPES, 1.5 M NaCl, 30 mM EDTA and
.5% v/v Surfactant P20; yielded pH 7.4 when diluted) was diluted and flowed over the sensor chip
hannels. All experiments were conducted at +25 C.
The immobilization buffer was previously selected using the pH scouting protocol, in which the
eptideantigen,solvedindifferentbuffers,wasflowedovertheinactivesensorchipfor120 sataflowrate
f 10 mL/min. The regeneration of the chip surface was performed with a pulse of 0.1 M NaOH for 30 s at a
ow rate of 10 mL/min after each solution injected. The immobilization buffers were used at pH between
.5 and the isoelectric point of the antigen in order to achieve the electrostatic pre-concentration of
lucopeptide in the dextran matrixof CM5 chip (pre-concentration is favored by low ionic strength in the
uffer). The best immobilization buffer was selected injecting the glucopeptide in 10 mM carbonate
uffer pH 9.6, PBS buffer pH 7.2,10 mM,1 mM and 0.1 mM acetate buffer at pH 4.5, 5.5 and 6.0. Buffers that
ive irregular sensorgrams or signals with irregular slopes, probably due to ligand aggregation/
recipitation or chip saturation, were discarded. The buffer 0.1 mM sodium acetate pH 5.5 presented the
ighest sensorgram slope and for this reason was selected as the optimal immobilization buffer.
lucopeptide antigen immobilization
The flow cell of the sensor chip surface was activated by injecting a 0.4 M 1-ethyl-3-(3-
imethylaminopropyl)-carbodiimide (EDC) and 0.1 M N-hydroxysuccinimide (NHS) mixture (50:50),
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prepared immediately before use, at a flow rate of 10 mL/min during 420 s. The glucopeptide CSF114
(Glc) was subsequently injected at 10 mL/min at a concentration of 10 mg/mL in the previously selected
immobilization buffer 0.1 mM sodium acetate pH 5.5, using the aim of immobilization procedure to
raise a final immobilization level of 800  100 resonance units (RU). Unreacted succinimide groups on
sensor chip surface were blocked by injecting 60 s-pulses of 1 M ethanolamine at pH 8.5 at 10 mL/min
until complete deactivation. One channel without immobilized ligand was used as reference, to
remove the non-specific signal depending on interactions between molecules present in the biological
samples and gold on sensor chip surface. At this purpose another different flow cell of the sensor chip
was activated and immediately blocked with ethanolamine.
Monitoring glucopeptide antigen-antibodies interaction: protocol optimization
Human serum samples were thawed till ambient temperature and then diluted 1:100 and/or
1:50 in running buffer. To establish a reproducible method for autoantibody detection, diluted serum
samples of a representative high positive patient and a healthy control were injected in triplicate at
flow rate of 30 mL/min over the immobilized glucopeptide at different contact times (range 60–240 s).
Dissociation was monitored for 60 s by injecting the running buffer suddenly after samples at a flow
rate of 30 mL/min. Interactions were recorded as separate sensorgrams and measurements registered
15 s after the end of each sample injection. Responses were measured in resonance units (RU) as the
difference between reference and active channel.
The selected optimal conditions include the 1:50 sera dilution injected for 240 s, which presented
increased signal differences between positive and negative samples maintaining low non-specific
interactions in the reference channel. After each sample injection, surface was regenerated with two
60 s pulses of a solution 100 mM NaOH allowing the complete removal of specifically and non-
specifically bounded biological material from the surface. Following this protocol all further
experiments were performed not over and above 100 measurements per channel.
The analytical variability of the assay was checked screening one characteristic high positive serum
at dilution 1:50 testing successively the same sample (15 runs) or in different experiments (12 runs
performed once a week). The within-assay and between-assay coefficients of variation (SE/mean)
were below 5% and then considered as a low signal average. This positive sample, and another sample
selected as negative control, can be used as control each 15 samples measurement during the
screening of a pool of sera, verifying the stability of the probe upon a large number of cycles. For each
measurement a sample volume of 150 mL was employed, thus small amount of 3 mL of patient serum
was required for each assay.
Calibration curve with purified antibodies
Immunoaffinity purified anti-CSF114(Glc) antibodies [5] from one high positive control serum
were injected at five different concentrations (from 1.25 mg/mL to 20 mg/mL) on the flow channels.
The running buffer was then flushed for 60 s and chip surface was regenerated with two injections of
100 mM NaOH during 60 s each one. All the steps were performed at a flow rate of 30 mL/min. The
resulting resonance signal was plotted against antibodies concentration to give the calibration curve
reported in Fig. 1. The obtained results showed a direct correspondence between the instrumental
signal and the antibodies concentration inside the sample, indicating that the herein proposed SPR
based method can be successfully applied to detect and to quantify polyclonal antibodies in human
serum specifically interacting with the immobilized glucopeptide antigen.
SPR binding studies with human sera
The specific antibody reactivity of Multiple Sclerosis patients’ sera against the immobilized CSF114
(Glc) antigen was evaluated according to the above described optimized protocol. Each sample was
tested in triplicate at a flow rate of 30 mL/min. Human sera were diluted 1:50 in running buffer and
were injected during 240 s followed by 60 s of buffer flow. After each measurement, chip surface was
regenerated injecting two pulses of a 100 mM NaOH solution during 60 s. Interaction of samples with

















1ensor chip flow cells were monitored as separate sensorgrams and measurements were taken 15 s
fter the end of each injection. The anti glucosylated peptide responses, measured in RU and resulting
rom the signal difference between active and reference channel, allowed a significant quantification
f specific antibodies present in patients' sera as compared to normal blood donors.
SPR-based analyte quantification is hard to perform when injecting a complex biological matrix as
ample. The present experiments demonstrated that, thanks to an appropriate covalent immobiliza-
ion strategy and to carefully optimized run parameters, SPR-based immunoassays can be successfully
sed to specifically detect antibodies of proven disease relevance, directly in patients’ sera without the
eed of any previous purification step.
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Fig. 1. Measured values registered at the different concentrations of purified anti-CSF114(Glc) antibodies.
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